A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
Fernando G ZampieriBruno R da CostaSuvi T VaaraFrançois LamontagneBram RochwergAlistair D NicholShay McGuinnessDanny F McAuleyMarlies OstermannRon WaldSean M Bagshawnull nullPublished in: Critical care (London, England) (2022)
In a Bayesian reanalysis of the STARRT-AKI trial, we found very low probability that an accelerated strategy has clinically important benefits compared with the standard strategy. Patients receiving the accelerated strategy probably have fewer days alive and KRT-free. These findings do not support the adoption of an accelerated strategy of KRT initiation.